Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares fell 5.1% on Tuesday . The stock traded as low as $49.35 and last traded at $50.09. 628,214 shares changed hands during trading, a decline of 19% from the average session volume of 778,760 shares. The stock had previously closed at $52.77.

Several research firms have recently weighed in on ESPR. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Bank of America Corporation restated a “neutral” rating and set a $60.00 price objective on shares of Esperion Therapeutics in a research note on Friday, August 11th. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, June 25th. Stifel Nicolaus restated a “buy” rating and set a $70.00 price objective (up from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Finally, Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and lowered their price objective for the stock from $85.00 to $55.00 in a research note on Tuesday, August 8th. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $51.65.

The company’s 50-day moving average price is $47.57 and its 200 day moving average price is $39.30. The company’s market cap is $1.11 billion.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the firm posted ($0.62) EPS. Equities research analysts forecast that Esperion Therapeutics, Inc. will post ($7.33) earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $158,000. Princeton Alpha Management LP bought a new position in shares of Esperion Therapeutics in the first quarter valued at approximately $205,000. Tower Research Capital LLC TRC boosted its position in shares of Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares during the period. Bank of Montreal Can boosted its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 6,000 shares during the period. Finally, Aperio Group LLC bought a new position in shares of Esperion Therapeutics in the second quarter valued at approximately $249,000. Institutional investors own 83.33% of the company’s stock.

WARNING: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/07/esperion-therapeutics-inc-espr-stock-price-down-5-1.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.